National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.6) (Cth)

PB 56 of 2023

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.6)

National Health Act 1953

___________________________________________________________________________

I, SOUMYA SUDARSHAN, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the National Health Act 1953.

Dated                   29 June 2023

SOUMYA SUDARSHAN

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1.......... Name............................................................................................................................................ 1

2.......... Commencement............................................................................................................................ 1

3.......... Authority...................................................................................................................................... 1

4.......... Schedules..................................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019  

1. Name

(1)This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.6).

(2)This instrument may also be cited as PB 56 of 2023.

1. Commencement

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 July 2023	1 July 2023

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1. Authority

This instrument is made under subsection 98C(1) of the National Health Act 1953.

4     Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

1. Schedule 3, entry for Buprenorphine

substitute:

Buprenorphine	Injection (modified release) 8 mg in 0.16 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 16 mg in 0.32 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 24 mg in 0.48 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 32 mg in 0.64 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 64 mg in 0.18 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 96 mg in 0.27 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 128 mg in 0.36 mL pre‑filled syringe
Buprenorphine	Injection (modified release) 160 mg in 0.45 mL pre-filled syringe
Buprenorphine	Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe
Buprenorphine	Tablet (sublingual) 400 micrograms (as hydrochloride)
Buprenorphine	Tablet (sublingual) 2 mg (as hydrochloride)
Buprenorphine	Tablet (sublingual) 8 mg (as hydrochloride)
Buprenorphine	Transdermal patch 5 mg
Buprenorphine	Transdermal patch 10 mg
Buprenorphine	Transdermal patch 15 mg
Buprenorphine	Transdermal patch 20 mg
Buprenorphine	Transdermal patch 25 mg
Buprenorphine	Transdermal patch 30 mg
Buprenorphine	Transdermal patch 40 mg

1. Schedule 3, after entry for Buprenorphine in the form Transdermal patch 40 mg

insert:

Buprenorphine with naloxone	Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)
Buprenorphine with naloxone	Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)

1. Schedule 3, entry for Methadone

substitute:

Methadone	Injection containing methadone hydrochloride 10 mg in 1 mL
Methadone	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL
Methadone	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL
Methadone	Tablet containing methadone hydrochloride 10 mg

1. Schedule 4, entry for Budesonide with formoterol in the form Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2

substitute:

Budesonide with formoterol Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses